According to a Phase 1 study published on August 28, 2026, in Nature Medicine, anti-CD19 CAR T cell therapy using mivocabtagene autoleucel (KYV-101) demonstrated targeted B-cell depletion without severe cytokine release syndrome events in six patients with treatment-refractory rheumatoid arthritis. Researchers from the COMPARE trial (NCT06475495) evaluated the safety and biomarker endpoints of the investigational therapy, laying the groundwork for an upcoming Phase 2 protocol that incorporates a randomized active comparator arm against rituximab.
Refractory Rheumatoid Arthritis Patient Population and EULAR Criteria
The Phase 1 cohort enrolled six patients ranging from 31 to 69 years of age, comprising an equal split of three women and three men, according to the Nature Medicine publication. All participants presented with seropositive rheumatoid arthritis and had failed multiple prior lines of therapy. This included conventional synthetic disease-modifying antirheumatic drugs (DMARDs) alongside at least one biologic DMARD prior to receiving the investigational cellular product.
This enrollment window reflects deliberate population breadth for a first-in-indication study. According to protocol analysis, sponsors running CD19 CAR T trials in hematologic malignancies typically skew younger, whereas including patients up to age 69 models the actual rheumatoid arthritis treatment-refractory population. The European Alliance of Associations for Rheumatology (EULAR) defines difficult-to-treat rheumatoid arthritis as the failure of at least two conventional DMARDs plus at least one biologic or targeted synthetic DMARD after adequate dosing. Anchoring eligibility to this threshold gives the U.S. Food and Drug Administration (FDA) a recognized reference frame when reviewing investigational new drug data packages, according to regulatory insights from clinical trial analysts.
Safety Monitoring and Single-Dose Phase 1 Architecture
The COMPARE trial investigates the safety of anti-CD19 CAR T cell therapy in Phase 1, while evaluating the safety of both CAR T cell therapy and rituximab in Phase 2, as outlined in trial documentation. The study protocol also seeks to assess anti-citrullinated protein antibody (ACPA) seroconversion—determining whether treatment drives ACPA negativity—as a key biomarker endpoint.
Unlike standard designs that establish single-agent safety before studying efficacy, the COMPARE protocol layers a head-to-head safety comparison with rituximab directly into Phase 2. The Phase 1 cohort received a single infusion of KYV-101, resulting in observed B-cell depletion consistent with the mechanism of action. Because sponsors did not run a classic 3+3 dose escalation, the single fixed dose indicates a prior determination that one level was clinically justified by the oncology safety database for KYV-101.
Did you know?
According to FDA early-phase cell therapy guidance, sponsors must explicitly justify dose selection in their investigational new drug application when utilizing a single-dose Phase 1 design.
Cytokine Release Syndrome Data and Toxicity Thresholds
The trial assessed safety outcomes including cytokine release syndrome and neurotoxicity, following standard monitoring frameworks for CD19-directed CAR T cell therapies. The Phase 1 cohort reported zero severe cytokine release syndrome events across all six patients.
Contextualizing this outcome requires looking at broader oncology baselines. According to a pooled analysis of 982 patients treated with CD19 CAR T for hematologic malignancies published in medical literature, the severe cytokine release syndrome rate reached 18.5%, with a 95% confidence interval spanning from 12.8% to 25.9%. In adult patients specifically, that rate sat at 16.1%. While six patients cannot establish a definitive rate estimate—with a 95% confidence interval around zero events running from 0% to roughly 46%—the profile successfully satisfies typical dose-limiting toxicity criteria to clear Phase 1 stopping rules and enable Phase 2 randomization.
Long-Term Hypogammaglobulinemia Monitoring in Autoimmune Protocols
Long-term immunoglobulin monitoring is integrated into the follow-up protocol to track B-cell depletion effects. According to data from a study of 579 patients treated with CD19-directed CAR T cell therapy, 90.6% developed hypogammaglobulinemia, characterized by immunoglobulin G levels at or below 600 milligrams per deciliter post-treatment. Mean immunoglobulin G levels fell from 587 milligrams per deciliter pre-treatment down to 362 milligrams per deciliter post-treatment.
While oncology patients with short expected survival horizons manage this trade-off, a rheumatoid arthritis patient achieving remission in their thirties or forties faces a dominant safety narrative regarding long-term infection risk. Regulators and payers will evaluate benefit-risk profiles heavily based on longitudinal follow-up duration and pre-specified immunoglobulin replacement intervention criteria.
Frequently Asked Questions
What is the primary objective of the COMPARE trial?
The COMPARE trial evaluates safety and biomarker endpoints—specifically ACPA seroconversion—in patients with active, ACPA-positive, treatment-refractory rheumatoid arthritis.
What is mivocabtagene autoleucel (KYV-101)?
Mivocabtagene autoleucel is a fully human anti-CD19 CAR T cell construct.
How does the trial define refractory rheumatoid arthritis?
The trial anchors eligibility in the EULAR definition of difficult-to-treat rheumatoid arthritis, requiring failure of conventional synthetic DMARDs and at least one biologic DMARD.
What are the key safety concerns associated with CD19 CAR T therapies?
Key monitoring requirements include cytokine release syndrome, neurotoxicity, and long-term hypogammaglobulinemia driven by sustained B-cell depletion.
Stay informed on clinical trial developments and regulatory updates. Subscribe to our newsletter or explore our latest analysis on cellular and gene therapies.
Keep reading